AMA Expresses Safety Concerns Over New Federal Policy on Compounded Peptides

The American Medical Association (AMA) has voiced significant patient safety concerns regarding a new U.S. Department of Health and Human Services (HHS) policy. This policy permits state-licensed pharmacies, federal facilities, or physicians to compound drug products using non-FDA-approved peptide bulk substances. The AMA warns that this increases patient risk due to insufficient evidence of these peptides' safety and efficacy.